Skip to main content
COGNITION THERAPEUTICS INC logo

COGNITION THERAPEUTICS INC — Investor Relations & Filings

Ticker · CGTX ISIN · US19243B1026 US Professional, scientific and technical activities
Open in API
Filings indexed 281 across all filing types
Latest filing 2022-12-29 Capital/Financing Update
Country US United States of America
Listing US CGTX

About COGNITION THERAPEUTICS INC

https://cogrx.com/

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company that discovers and develops oral, small-molecule therapeutics for neurodegenerative disorders. The company's primary focus is on conditions such as Alzheimer's disease and Dementia with Lewy Bodies (DLB). Its therapeutic approach is centered on developing medications designed to target and modulate key cellular damage response mechanisms. By aiming to rescue trafficking deficits and restore normal cellular housekeeping functions, the company seeks to protect neurons, improve synaptic health, and ultimately address the cognitive decline associated with these diseases.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2022
Capital/Financing Update Classification · 95% confidence The document is a letter from Cognition Therapeutics, Inc. to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It references the Registration Statement filing and requests the SEC to declare it effective at a specified time. The document is short (1802 characters) and is a formal communication related to a regulatory filing process, not the filing itself or a financial report. It does not contain financial data or detailed report content but is an administrative request related to capital raising. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as registration statements for securities offerings.
2022-12-29 English
Regulatory Filings 2022
Regulatory Filings Classification · 80% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Due to the lack of identifiable information and the inability to determine the nature of the document, it cannot be classified into any specific filing category based on the given text. According to the fallback rule, documents that do not fit into any specific category should be classified as Regulatory Filings (RNS). The document length is sufficient to exclude it being a mere announcement or certification, but the content is unreadable and non-informative.
2022-12-28 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 23, 2022, by Cognition Therapeutics, Inc. The key content is the announcement of entering into a Controlled Equity Offering Sales Agreement to potentially sell up to $40 million of common stock. This is a clear update on the company's capital raising activities and financing arrangements. There are no financial statements or detailed financial results presented, only the description of the financing agreement and related terms. The document is not an annual or quarterly report, nor is it a proxy, earnings release, or management discussion. It fits the category of Capital/Financing Update, which covers company fundraising and capital structure changes. The document length is 5719 characters, sufficient to contain substantive information about the financing agreement rather than a mere announcement of a report publication. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-12-23 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for public offering. It includes a base prospectus and a sales agreement prospectus for offering common stock, preferred stock, debt securities, warrants, subscription rights, and units. The document is not a financial report, earnings release, or management discussion but a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, confirming it is not a brief announcement or a report publication notice.
2022-12-23 English
SC 13D/A
Major Shareholding Notification
2022-12-05 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2022-11-29 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.